Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
Alle Spezies anzeigen
Weitere Synonyme anzeigen
Wählen Sie die Spezies und Applikation aus
anti-Rat (Rattus) C-MYC Antikörper:
anti-Mouse (Murine) C-MYC Antikörper:
anti-Human C-MYC Antikörper:
Sie gelangen zu unserer vorgefilterten Suche.
Human Monoclonal C-MYC Primary Antibody für FM, IHC (fro) - ABIN967320
Blackwood, Eisenman: Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. in Science (New York, N.Y.) 1991
Show all 13 Pubmed References
Human Monoclonal C-MYC Primary Antibody für FACS, IHC (p) - ABIN302092
Veracini, Simon, Richard, Schraven, Horejsi, Roche, Benistant: The Csk-binding protein PAG regulates PDGF-induced Src mitogenic signaling via GM1. in The Journal of cell biology 2008
Show all 14 Pubmed References
Human Monoclonal C-MYC Primary Antibody für FACS, IHC (p) - ABIN302017
Wang, Campoli, Ko, Luo, Ferrone: Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies. in Journal of immunological methods 2004
Show all 15 Pubmed References
Chicken Monoclonal C-MYC Primary Antibody für ChIP, CyTOF - ABIN152253
Locker, Dowle, Ellis, Elston, Blamey, Sikora, Evan, Robins: c-myc oncogene product expression and prognosis in operable breast cancer. in British journal of cancer 1989
Show all 10 Pubmed References
All Species Monoclonal C-MYC Primary Antibody für FACS, IP - ABIN2749043
Persson, Hennighausen, Taub, DeGrado, Leder: Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. in Science (New York, N.Y.) 1984
Show all 15 Pubmed References
All Species Monoclonal C-MYC Primary Antibody für IHC, IHC (p) - ABIN4994828
Hilpert, Hansen, Wessner, Küttner, Welfle, Seifert, Höhne: Anti-c-myc antibody 9E10: epitope key positions and variability characterized using peptide spot synthesis on cellulose. in Protein engineering 2001
Show all 6 Pubmed References
Human Monoclonal C-MYC Primary Antibody für FACS, IHC (p) - ABIN536092
Fujiwara, Poikonen, Aleman, Valtavaara, Saksela, Mayer: A single-chain antibody/epitope system for functional analysis of protein-protein interactions. in Biochemistry 2002
Show all 3 Pubmed References
Human Monoclonal C-MYC Primary Antibody für IHC (fro), IF - ABIN2477762
Quant, Woo: Normal values of eye position in the Chinese population of Hong Kong. in Optometry and vision science : official publication of the American Academy of Optometry 1992
Show all 4 Pubmed References
Human Monoclonal C-MYC Primary Antibody für IF, WB - ABIN3201011
Khanna, Böckelman, Hemmes, Junttila, Wiksten, Lundin, Junnila, Murphy, Evan, Haglund, Westermarck, Ristimäki: MYC-dependent regulation and prognostic role of CIP2A in gastric cancer. in Journal of the National Cancer Institute 2009
Show all 2 Pubmed References
In a mouse lung model of KRas(G12D)-driven adenomas, co-activation of Myc drives the immediate transition to highly proliferative and invasive adenocarcinomas marked by highly inflammatory, angiogenic, and immune-suppressed stroma.
the role of phosphorylation on AID serine38 in AID activity at the Immunoglobulin switch region and off-target Myc gene, is reported.
This study demonstrates that LMP2A uses the role of MYC in the cell cycle, particularly in the p27(kip1 (zeige CDKN1B Antikörper)) degradation process, to accelerate lymphomagenesis in vivo.
Results show Myc to be dispensable for sustained in vivo hepatocyte proliferation but necessary for maintaining normal lipid homeostasis.
Data show that the induction of BIM (zeige BCL2L11 Antikörper) in the MYC- and RAS-driven leukemia is mediated by the downregulation of miR-17-92, and suggest that induction of BIM (zeige BCL2L11 Antikörper)-mediated apoptosis may be a therapeutic approach for acute lymphoblastic leukemia (ALL).
Pin1 (zeige PIN1 Antikörper) silencing in lymphomas retarded disease progression in mice, making Pin1 (zeige PIN1 Antikörper) an attractive therapeutic target in Myc-driven tumors.
beta-catenin (zeige CTNNB1 Antikörper) cooperates with the transcription factor Myc to activate the progenitor renewal program.
Gfi1 (zeige ZNF163 Antikörper) disruption antagonized the tumor-promoting effects of Ezh2 (zeige EZH2 Antikörper) loss; conversely, Gfi1 (zeige ZNF163 Antikörper) overexpression collaborated with Myc to bypass effects of Trp53 (zeige TP53 Antikörper) inactivation in driving medulloblastoma progression in primary cerebellar neuronal progenitors.
rather than via E-Box binding, cMyc acts in the dorsal neural tube by interacting with another transcription factor, Miz1 (zeige PIAS2 Antikörper), to promote self-renewal. The finding that cMyc operates in a non-canonical manner in the premigratory neural crest highlights the importance of examining its role at specific time points and in an in vivo context.
miR-17-92-dependent tuning of LKB1 (zeige STK11 Antikörper) levels regulates both the metabolic potential of Myc+ lymphomas and tumor growth in vivo.
Apoptosis was also observed with myca expression; introduction of homozygous tp53 (zeige TP53 Antikörper)(-/-) mutation into the myca transgenic fish reduced apoptosis and accelerated tumor progression.
MYC down-regulation induces mitochondrial apoptosis in T lymphoblasts.
High c-Myc expression is associated with tumor metastasis and poor prognosis in human melanoma. c-Myc upregulates Snail (zeige SNAI1 Antikörper) expression to promote EMT (zeige ITK Antikörper) via the TGF-beta (zeige TGFB1 Antikörper)/Snail (zeige SNAI1 Antikörper)/Ecadherin signal pathway.
Myc activation in glioblastoma generates a dependency on glycolysis and an addiction to metabolites required for glycolysis.
Diverse gastric cancer cell lines of Asian and Brazilian origins differ in BRD4 (zeige BRD4 Antikörper) and c-MYC expression levels and sensitivity to BET inhibitors.
We conclude that 8q24/MYC rearrangement in chronic lymphocytic leukemia is rare and often acquired during the course of disease
ruthenium(II) complexes can be developed as potential inhibitors in chemotherapy through their binding and stabilization of c-myc G-quadruplex DNA.
IGF-II siRNA inactivates the FAK (zeige PTK2 Antikörper)/PI3K (zeige PIK3CA Antikörper)/Akt (zeige AKT1 Antikörper) signaling pathway, and further reduces cell proliferation, N-ras (zeige NRAS Antikörper) and C-myc levels in SMMC-7721 cells.
Data show that Islet-1 (ISL1 (zeige ISL1 Antikörper)) activated the expression of cyclin B1 (CCNB1 (zeige CCNB1 Antikörper)), cyclin B2 (CCNB2 (zeige CCNB2 Antikörper)) and c-myc (c-MYC) genes by binding to the conserved binding sites on their promoters or enhancers.
IRS1 (zeige IRS1 Antikörper)/beta-Catenin (zeige CTNNB1 Antikörper) Axis Is Activated and Induces MYC Expression in Acute Lymphoblastic Leukemia Cells
Data show that inactivated Sendai virus (HVJ-E)-induced apoptosis is associated with c-Myc downregulation.
Data show that ME47, a designed small minimalist hybrid protein (MHP (zeige CACNA1A Antikörper)), binds to E-box binding sites of MYC target genes, suggesting an alternative therapeutic targeting system that can be used to target transcription factors important in diseases, including cancer.
report the isolation of complete coding regions of rabbit SOX2, KLF4, C-MYC and NANOG, which encode transcription factors that play crucial regulatory roles during early mammalian embryonic development
Ouabain-induced proliferation might be attributed, at least in part, to decrease of intracellular free calcium and increase of c-myc mRNA expression, and that may be directly or indirectly involved in regulation of blood pressure.
The protein encoded by this gene is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene.
v-myc myelocytomatosis viral oncogene homolog
, Avian myelocytomatosis viral (v-myc) oncogene homolog
, myc proto-oncogene protein
, myelocytomatosis viral oncogene homolog
, proto-oncogene c-Myc
, transcription factor p64
, v-myc avian myelocytomatosis viral oncogene homolog
, c-myc proto-oncogene
, cellular myelocytomatosis oncogene
, transcriptional regulator Myc-A
, avian myelocytomatosis viral oncogene homolog
, class E basic helix-loop-helix protein 39
, myc-related translation/localization regulatory factor
, avian myelocytomatosis viral (v-myc) oncogene homolog
, Proto-oncogene c-Myc
, Transcription factor p64
, Myc proto-oncogene protein